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Objective: Mesenchymal stem cells (MSCs) are multipotent stromal 
cells that can differentiate into a variety of cell types. They control the 
process of hematopoiesis by secreting regulatory cytokines and growth 
factors and by the expression of important cell adhesion molecules for 
cell-to-cell interactions. This investigation was intended to examine 
the effect of bone marrow (BM)-derived MSCs on the differentiation 
of HL-60 cells according to morphological evaluation, flow cytometry 
analysis, and gene expression profile. 
Materials and Methods: The BM-MSCs were cultured in Dulbecco’s 
modified Eagle’s medium supplemented with 10% fetal bovine serum 
(FBS). After the third passage, the BM-MSCs were irradiated at 30 
Gy. To compare how the HL-60 cells differentiated in groups treated 
differently, HL-60 cells were cultured in RPMI-1640 and supplemented 
with 10% FBS. The HL-60 cells were seeded into six-well culture 
plates and treated with all-trans-retinoic acid (ATRA), BM-MSCs, or 
BM-MSCs in combination with ATRA, while one well remained as 
untreated HL-60 cells. The expression levels of the granulocyte subset-
specific genes in the HL-60 cells were assayed by real-time polymerase 
chain reaction. 
Results: Our results revealed that BM-MSCs support the granulocytic 
differentiation of the human promyelocytic leukemia cell line HL-60. 
Conclusion: Based on the results of this study, we concluded that 
BM-MSCs may be an effective resource in reducing or even preventing 
ATRA’s side effects and may promote differentiation for short 
medication periods. Though BM-MSCs are effective resources, more 
complementary studies are necessary to improve this differentiation 
mechanism in clinical cases.
Keywords: Mesenchymal stem cells, HL-60 cells, Differentiation, All-
trans-retinoic acid
Amaç: Mezankimal kök hücreler (MKH) birçok hücre tipine göre 
farklılaşabilen multipotent stromal hücrelerdir. Hematopoez sürecini 
düzenleyici sitokinler ve büyüme faktörleri salınımı ile ve hücreler arası 
etkileşim için önemli hücresel adezyon moleküllerinin ifadesi yoluyla 
kontrol ederler. Bu çalışma da kemik iliği (Kİ) kaynaklı MKH HL-60 
hücrelerinin farklılaşması üzerine etkisini morfolojik değerlendirme, 
akım sitometri ve gen ifade analizi yöntemleriyle araştırılması 
amaçlanmıştır. 
Gereç ve Yöntemler: Kİ-MKH %10 fetal sığır serumu (FSS) içeren 
Dulbecco’nun modifiye Eagle ortamında kültür edildi. Üçüncü 
pasaj sonrası, Kİ-MKH 30 Gy ile ışınlandı. HL-60 hücrelerinin farklı 
şartlarda nasıl farklılaştığını karşılaştırmak için HL-60 hücreler %10 
FSS eklenmiş RPMI-1640 ortamında kültür edildi. HL-60 hücreleri altı 
kuyucuklu plaklarda all-trans retinoik asit (ATRA), Kİ-MKH ve ATRA 
ile birlikte Kİ-MKH ile muamele edilirken, bir kuyucuğa sadece HL-
60 hücreleri kondu. HL-60 hücrelerinde granülosit alt gruplarına özgü 
genlerin ifade düzeyleri gerçek zamanlı polimeraz zincir reaksiyonu ile 
değerlendirildi. 
Bulgular: Sonuçlarımız Kİ-MKH’nin insan promiyelositik lösemi hücre 
dizisi HL-60’ın granülositik farklılaşmasını desteklediğini gösterdi. 
Sonuç: Bu çalışmanın bulgularına göre, Kİ-MKH’nin ATRA yan etkilerini 
azaltıcı ve hatta önleyici etkili bir kaynak olduğu ve kısa ilaç kullanımı 
süreçlerinde farklılaşmayı uyarabileceği sonucunu çıkarttık. Kİ-MKH 
etkili bir kaynak olsa da, klinik olgularda bu farklılaşma mekanizmasını 
iyileştirmek için destekleyici ek çalışmalara ihtiyaç vardır. 
Anahtar Sözcükler: Mezankimal kök hücreler, HL-60 hücreleri, 
Farklılaşma, All-trans retinoik asit
ÖzAbstract
1Tabriz University Faculty of Medicine, Hematology and Oncology Research Center, Tabriz, Iran
2Tabriz University Faculty of Medicine, Drug Applied Research Center, Tabriz, Iran
3Tabriz University Faculty of Medicine, Department of Immunology, Tabriz, Iran
4Mazandaran University Faculty of Medicine, Amol Faculty of Paramedical Sciences, Sari, Iran
5Hamline University Faculty of Medicine, Department of Biology, Minnesota, USA
 Hossein Nikkhah1,  Elham Safarzadeh2,3,  Karim Shamsasenjan1,  Mehdi Yousefi2,3,  Parisa Lotfinejad1,3,  Mehdi Talebi1, 
 Mozhde Mohammadian4,  Farhoud Golafshan5,  Aliakbar Movassaghpour1
Kemik İliği Mezankimal Hücrelerinin HL-60 Hücrelerindeki Granülositik Farklılaşması 
Üzerine Etkisi
The Effect of Bone Marrow Mesenchymal Stem Cells on the 
Granulocytic Differentiation of HL-60 Cells
DOI: 10.4274/tjh.2016.0498 
Turk J Hematol 2018;35:42-48
43
Turk J Hematol 2018;35:42-48
Introduction
There are different cell types of the osteoblast lineage in bone 
and the bone marrow, the most primitive of them being the 
mesenchymal stem cells (MSCs) [1,2]. MSCs can differentiate into 
several types of cells and produce important growth factors and 
cytokines [3,4]. MSCs are defined by the International Society 
of Cellular Therapy based on three properties: the adherence to 
plastic in standard culture; the expression of CD105, CD73, and 
CD90 and lack of expression of CD45, CD34, CD14 or CD11b, 
CD79α or CD19, and HLA class II; and differentiation potential 
into osteocytes, adipocytes, and chondrocytes [5,6]. These cells 
are involved in the regulation of hematopoietic precursor cell 
proliferation and differentiation [7,8].
All-trans-retinoic acid (ATRA) has a potential role in treating 
acute myeloid leukemia (AML) and some hematological 
disorders [9]. It has been recognized that ATRA induces the 
differentiation of myeloid leukemic cells through growth 
inhibition [10]. Many studies have reported severe adverse 
effects of ATRA. Therefore, novel therapeutic strategies need 
to be developed to decrease ATRA’s potential side effects and 
enhance the efficacy of this drug. One possible approach is the 
use of ATRA-based combinations that are more efficient than 
the single components [11,12,13]. The roles of the various cells 
in the bone marrow niche are unclear in the differentiation of 
hematopoietic stem cells, and MSCs, as the precursors of the 
cellular components, are important cells of the bone marrow 
niche [14]. To understand the precise interaction between MSCs 
and leukemic cells, in the current study we investigated whether 
MSCs affect the differentiation of HL-60 cells.
Materials and Methods
Cell Culture
Human promyelocytic leukemia cell line HL-60 (a kind gift 
from Dr. Abroun, Tarbiat Modares University, Tehran, Iran) 
was cultured in RPMI-1640 medium (Sigma-Aldrich, St. 
Louis, MO, USA) supplemented with 10% fetal bovine serum 
(HyClone, Logan, UT, USA), 100 U/mL penicillin, and 100 µg/mL 
streptomycin (Sigma, St. Louis, MO, USA). The BM-MSCs (Stem 
Cell Technology, Tehran, Iran) were cultured in low-glucose 
Dulbecco’s modified Eagle medium (GIBCO BRL, Gaithersburg 
MD, USA) containing 10% fetal bovine serum.
Co-culture Experiments
HL-60 cells (105 cells/mL) were seeded onto plates and treated 
with ATRA at a concentration of 5x10-7 M (Sigma-Aldrich) for 
48 h. The co-culture experiments were performed in six-well 
plates including the HL-60 cells treated with BM-MSCs or those 
treated with BM-MSCs and 5x10-7 M ATRA together. Before co-
culturing with cancer cells, the BM-MSCs were irradiated at 30 
Gy when they reached 60% confluence. The HL-60 cells came 
into direct contact with the BM-MSCs.
Morphological Study of Differentiated Granulocyte Cells
To study the morphological changes, the HL-60 cells were 
treated with ATRA, BM-MSCs, or a combination of ATRA and 
BM-MSCs. After 48 h of incubation, the cells were stained with 
Wright-Giemsa stain and studied by light microscope.
Flow Cytometric Assessment of Granulocytic Markers for 
Differentiation
The HL-60 cells (1x106) of the different groups, the co-culture 
of the HL-60 cells with BM-MSCs, the HL-60 cells with BM-
MSCs and ATRA in combination, the HL-60 cells with ATRA as 
a positive control, and the HL-60 cells without additions as a 
negative control were harvested and incubated with FITC-
labeled anti-CD11b (Becton Dickinson, San Jose, CA, USA) for 30 
min at 4 °C. The cells were then analyzed for the evaluation of 
CD11b expression (a myeloid differentiation marker) with a flow 
cytometer (Becton Dickinson).
Real-Time Polymerase Chain Reaction
The expression of the granulocyte subset-specific genes in the 
treated HL-60 cells was investigated by real-time polymerase 
chain reaction (RT-PCR) after an incubation period of 48 h. 
Total RNA was extracted using the QIAzol lysis reagent (QIAGEN, 
Germantown, MD, USA) according to the manufacturer’s 
instructions. The cDNA was prepared according to the 
instructions of the Revert Aid Single Strand Kit (Fermentas, 
Burlington, ON, Canada). The mRNA levels of PU.1, CD11b, 
lysozyme, C/EBP-ALPHA, C/EBP-BETA, C/EBP E, MPO, CD64, 
CD16, GCSFR, and cathepsin G were analyzed using qRT-PCR. 
The GAPDH gene was used as an internal control (Table 1).
Statistical Analysis
Data were reported as mean ± standard deviation and were 
analyzed using Graph Pad Prism v 5.00 (Graph Pad Software, Inc., 
La Jolla, CA, USA). Student’s t-test for single comparisons and two-
way ANOVA for multigroup comparisons were used for analysis 
and p<0.01 was regarded as denoting statistical significance.
Results
Flow Cytometry Confirmation of the Nature of the BM-MSCs
To verify the mesenchymal nature of the BM-MSCs, the surface 
antigens were assessed by flow cytometry, including CD14, 
CD19, CD34, CD45 CD90, CD105, and CD73. The characterization 
experiments performed in our study demonstrated that the 
BM-MSCs were negative in the expression of the hematopoietic 
markers for CD14, CD19, CD34, and CD45, and they had positive 
expression for CD90, CD105, and CD73 markers (Figure 1).
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Morphological Changes of the Treated Cells
To assess the morphological changes in the treated HL-60 cells, 
Wright-Giemsa staining was performed (Figures 2A-2D). The 
comparative study of the morphological changes in the HL-60 
cells stained by Wright-Giemsa indicated that, in comparison to 
the control, the cells treated with ATRA and BM-MSCs individually 
had induced granulocytic differentiation of the HL-60 cells 
(Figures 2B and 2C) and showed an additive effect when used 
with BM-MSCs in combination with ATRA (Figure 2D). While the 
control cells (Figure 2A) demonstrated typical morphology in the 
promyelocytic cells (a circular nucleus), the treated HL-60 cells 
exhibited a kidney-shaped nucleus and segmented nucleus and 
also had a reduced nuclear/cytoplasmic ratio.
Figure 1. Flow cytometry analysis confirmed the mesenchymal nature of the bone marrow mesenchymal stem cells. The markers assessed 
by flow cytometry included CD14, CD19, CD34, CD45 CD90, CD105, and CD73. The experiments were done in triplicate. 
Table 1. Primers for real-time polymerase chain reaction.
Gene name Forward primer Reverse primer
PU.1 GACACGGATCTATACCAACGCC CCGTGAAGTTGTTCTCGGCGAA
CD11b GGAACGCCATTGTCTGCTTTCG ATGCTGAGGTCATCCTGGCAGA
Lysozyme ACTACAATGCTGGAGACAGAAGC GCACAAGCTACAGCATCAGCGA
C/EBP-α AGGAGGATGAAGCCAAGCAGCT AGTGCGCGATCTGGAACTGCAG
C/EBP-β AGAAGACCGTGGACAAGCACAG CTCCAGGACCTTGTGCTGCGT
C/EBP E CCAGCCTCTGCGCGTTCTCAA CAAGGCTATCTTTGTTCACTGCC
MPO GAGCAGGACAAATACCGCACCA AGAGAAGCCGTCCTCATACTCC
CD16 GGTGACTTGTCCACTCCAGTGT ACCATTGAGGCTCCAGGAACAC
GCSFR CCACTACACCATCTTCTGGACC GGTGGATGTGATACAGACTGGC
Cathepsin G CGACAGTACCATTGAGTTGTGCG TTCGTCCATAGGAGACAATGCCC
MPO: Myeloperoxidase.
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CD11b Expression Increased in Treated HL-60 Cells
In the treated HL-60 cells, an increase was observed in the 
percentage of CD11b marker expression, one of the main 
granulocytic differentiation markers measured by flow 
cytometry, after 48 h. Flow cytometry results displayed that 
the expression of the CD11b marker was 17.12%, 76.69%, 
23.96%, and 96.4% in the untreated HL-60 cells, in the HL-60 
cells treated with ATRA, in the HL-60 cells treated with BM-
MSCs, and in the HL-60 cells treated with a combination of 
BM-MSCs and ATRA, respectively (Figure 3). The expression of 
CD11b significantly increased in the HL-60 cells treated with 
the combination of BM-MSCs and ATRA compared to the HL-60 
cells treated with ATRA alone or with BM-MSCs alone.
Effects of BM-MSCs and ATRA on Gene Expression in HLA-60 
Cells
In the ATRA-treated HL-60 cells, there was a marked increase 
(p<0.05) in the gene expressions of CD11b, lysozyme, GCSFR, 
CD64, PU.1, and C/EBP-ALPHA from 1.00 to 8.33 (±0.07), 5.53 
(±0.16), 3.36 (±0.12), 1.94 (±0.02), 1.26 (±0.04), and 1.11 (±0.02), 
respectively. There was no gene expression for C/EBP-BETA, 
C/EBP E, or CD16 (Figure 4). On the other hand, as revealed in 
Figure 4, in the HL-60 cells co-cultured with the BM-MSCs, 
there was significant increase (p<0.05) in CD11b, lysozyme, PU.1, 
CD64, and GCSFR expression levels from 1.00 to 2.2 (±0.07), 3.3 
(±0.16), 1.23 (±0.02), 1.11 (±0.02), and 1.51 (±0.12), respectively, 
and there was no expression of C/EBP-BETA, C/EBP E, or CD16 
levels. In the HL-60 cells co-cultured with the combination of 
BM-MSCs and ATRA, the gene expression of CD11b, lysozyme, 
CD64, GCSFR, C/EBP-ALPHA, and PU.1 was markedly increased 
(p<0.05) from 1.00 to 12.26 (±0.07), 7.19 (±0.16), 1.92 (±0.02), 
4.77 (±0.12), 1.31(±0.02), and 1.18 (±0.04), respectively. There was 
no expression for C/EBP-BETA, C/EBP E, or CD16 (Figure 4). The 
myeloid differentiation was characterized by downregulation of 
myeloperoxidase (MPO), a major protein expressed in myeloid 
cells. We assessed the mRNA level of MPO by RT-PCR after 48 h 
of treatment. The BM-MSCs, like ATRA, tended to decrease the 
MPO transcription (Figure 4).
Discussion
MSCs can support hematopoiesis by producing soluble factor(s) 
and also by the expression of cell adhesion molecules that are 
important for cell-to-cell interaction [15]. MSCs have been the 
subject of particular interest in recent years due their great 
potential for treating various diseases, especially those related 
to immune system disorders. However, there are controversial 
opinions on the role of MSCs in malignancies [16,17,18,19].
In recent years, several groups investigated the possible role of MSCs 
in influencing the behavior of tumor cells [20,21]. These studies 
Figure 2. BM-MSCs induced the granulocytic differentiation 
of HL-60 cells after 48 h of incubation and showed an additive 
effect with all-trans-retinoic acid (ATRA). The differentiation 
of the HL-60 cells was assessed by Wright-Giemsa staining: 
a) untreated HL-60 cells, b) HL-60 cells treated with ATRA, c) HL-
60 cells treated with bone marrow mesenchymal stem cells, d) 
HL-60 cells treated with ATRA and BM-MSCs. Magnitude: 100x. 
Figure 3. The flow cytometric analysis of CD11b, a granulocytic 
differentiation marker, after 48 h: a) untreated HL-60 cells, b) HL-
60 cells treated with BM-MSCs, c) HL-60 cells co-cultured with 
all-trans-retinoic acid (ATRA), d) HL-60 cells treated with BM-
MSCs and ATRA. BM-MSCs and ATRA synergistically upregulated 
CD11b expression in cells treated with the combination of the 
two. The experiments were done in triplicate. 
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mostly focused on the proliferation and apoptosis of cancer cells, 
but little is known about the effect of MSCs in the differentiation 
of leukemic cells [22]. It has been shown that substances such 
as ursolic acid, 12-O-tetradecanoylphorbol 13-acetate, and 
1,25-dihydroxyvitamin D3 [1,25(OH)2D3] inhibit the proliferation 
of and promote the monocyte/macrophage differentiation of 
AML HL-60 cells. A secosteroid, 1,25(OH)2D3 has a potential role 
in the differentiation of the cells of the myeloid lineage in vitro 
and ex vivo. This ability results in the use of 1,25(OH)2D3 to treat 
myelodysplastic syndromes or AML. However, 1,25(OH)2D3 leads 
to the partial differentiation of the hematopoietic blast cells and 
hypercalcemia, which is a limiting factor in its clinical application 
[23,24]. Differentiation therapy in APL patients with ATRA alone or 
in combination with chemotherapy has made great breakthroughs 
and results in high rates of complete clinical remission. However, 
it has potentially fatal side effects, such as retinoic acid syndrome 
and the development of resistance to this drug [13,25]. Repeated 
treatment with ATRA results in progressive resistance that it is 
attributed to the decrease of the ATRA serum level, which may 
be caused by accelerated clearance [26]. The use of ATRA in 
combination is one possible method to increase the therapeutic 
efficacy of this drug. Therefore, increasing efforts have been 
focused on developing alternative differentiation-promoting 
therapeutic methods with fewer side effects [22]. MSCs possess 
great advantages in research and clinical applications because of 
their better expandability, sufficient supply, and painless collection 
process [27].
Previous studies have shown that ATRA induces morphological 
differentiation of HL-60 cells. The results from this study 
indicated that ATRA, BM-MSCs, and ATRA in combination with 
BM-MSCs promote the differentiation of HL-60 cells compared 
to untreated cells. It should be added that the HL-60 cells 
treated with both ATRA and BM-MSCs appeared more mature, 
presenting band-form nuclei and segmented nuclei, compared 
to cells treated with either ATRA or the BM-MSCs alone (Figure 
2). Matching of the morphological and immunophenotypic data 
is critical, so immunophenotypic evaluations were performed. 
The proliferating HL-60 cells, in contrast to monocytes and 
Figure 4. Gene expression during differentiation of the HL-60 cells after 48 h: a) PU.1 gene expression, b) CD11b gene expression, c) 
lysozyme gene expression, d) C/EBP-alpha gene expression, e) myeloperoxidase gene expression, f) CD64 gene expression, g) GCSFR gene 
expression, h) cathepsin G gene expression. The experiments were performed in triplicate. *p<0.05. 
MPO: Myeloperoxidase, ATRA: all-trans-retinoic acid.
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neutrophils, do not express the CD11b marker, the b-subunit 
of integrin-aMb2 (also known as CD11b/CD18, MAC-1, or 
CR3). It was demonstrated that most HL-60 cells, following 
treatment with D3 (90% at 3-4 days) or ATRA (80% at 4-5 
days), become CD11b-positive [28]. As shown in Figure 3, the 
morphological data were further confirmed by the results of 
the immunophenotyping of CD11b. After 48 h of treatment, the 
expression of the CD11b marker in the HL-60 cells co-cultured 
with BM-MSCs in combination with ATRA was higher than 
that in the HL-60 cells co-cultured with BM-MSCs or ATRA 
individually. Therefore, we concluded that BM-MSCs induce the 
granulocytic differentiation of HL-60 cells.
Our data described the changes in the gene expression pattern 
during the transformation of the proliferating HL-60 cells into 
mature cells. One of the important factors that regulate the 
differentiation of HSCs along the myeloid lineage towards 
granulocytes rather than monocytes is CCAAT-enhancer 
binding protein-alpha (C/EBP-ALPHA). Indeed, C/EBP alpha 
knock-out mice demonstrate an early block in granulocytic 
differentiation [29]. The results of this study indicate that the 
BM-MSCs enhance ATRA’s effect on the amplification of C/EBP-
ALPHA transcription, but the BM-MSCs alone were upregulated 
without statistical significance. Our data also showed that the 
BM-MSCs and ATRA synergistically increased the expression of 
the CD11b and lysozyme genes.
In this study, we found an increased level of gene expression 
of PU.1 in the three groups of experiments compared to the 
untreated cells. Interestingly, we observed no significant 
synergistic effect in the HL-60 cells treated with ATRA in 
combination with the BM-MSCs. PU.1 has a critical role in the 
growth and development of hematopoietic cells. Several studies 
reported that PU.1-deficient mice lack mature myeloid lineages 
[30,31]. Uchino et al. [32] reported that the expression of the 
G-CSF receptor, contrary to their hypotheses, was downregulated 
after treatment with ATRA. The G-CSF receptor is present in the 
progenitor cells in the bone marrow, which is involved in the 
differentiation of the granulocytes through induction of G-CSF 
[33]. In our study, ATRA upregulated the expression of the G-CSF 
receptor gene and the use of the BM-MSCs in combination with 
ATRA synergistically enhanced ATRA’s effect on the expression of 
this gene, which may demonstrate the critical role of the G-CSF 
receptor in the promotion of differentiation in promyelocytic 
leukemia cells. Furthermore, in line with our hypothesis, the 
treatment with ATRA downregulated the expression of the MPO 
gene, but the BM-MSCs in combination with ATRA did not have 
a synergistic effect on the expression of this gene.
Conclusion
Our results demonstrated that BM-MSCs could promote the 
granulocytic differentiation of HL-60 cells and could elicit 
an additive effect when used in combination with ATRA. 
Consequently, our data highlight the critical role of BM-MSCs 
in the granulocytic differentiation of HL-60 cells and the use of 
BM-MSCs and ATRA in combination could be a novel therapeutic 
strategy for AML patients.
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